Senologie - Zeitschrift für Mammadiagnostik und -therapie, Inhaltsverzeichnis Senologie - Zeitschrift für Mammadiagnostik und -therapie 2008; 5(1): 24-26DOI: 10.1055/s-2008-1077170 Aktuell diskutiert © Georg Thieme Verlag KG Stuttgart · New YorkRecommendations of the Swiss Breast Cancer Expert Forum - Adjuvant therapy of HER2-positive breast cancer with trastuzumabArtikel empfehlen Abstract Volltext Referenzen References: 01 Piccart-Gebhart MJ . et al . Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353 1659-1672 02 Romond EH . et al . Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353 1673-1684 03 Slamon D, Eiermann W, Robert N et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2-positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 2005; 94: S5 (supp 1; abstr 1). 04 Press MF . et al . Diagnostic evaluation of HER2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res. 2005; 11 6598-6607 05 Suter TM, Ewer MS. Trastuzumab-Associated Cardiotoxicity. In Cancer and the Heart. BC Decker 2006.
